Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Compugen (NASDAQ:CGEN – Get Free Report) had its target price raised by investment analysts at Stifel Nicolaus from $3.00 to $4.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ price target suggests a potential upside of […]
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the
Under the terms of the deal, Gilad will make an immediate payment of $60 million to Compugen with potential milestone payments of up to $890 million plus royalties.
Compugen Ltd. (NASDAQ:CGEN – Get Free Report) has received an average rating of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year price objective among analysts […]
Shares of Compugen Ltd. (NASDAQ:CGEN – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 […]